The University of Southampton
University of Southampton Institutional Repository
Warning ePrints Soton is experiencing an issue with some file downloads not being available. We are working hard to fix this. Please bear with us.

Resolvin E1, resolvin D1 and resolvin D2 inhibit constriction of rat thoracic aorta and human pulmonary artery induced by the thromboxane mimetic U46619

Resolvin E1, resolvin D1 and resolvin D2 inhibit constriction of rat thoracic aorta and human pulmonary artery induced by the thromboxane mimetic U46619
Resolvin E1, resolvin D1 and resolvin D2 inhibit constriction of rat thoracic aorta and human pulmonary artery induced by the thromboxane mimetic U46619
Background and Purpose: Omega-6 fatty acid-derived lipid mediators such as prostanoids, thromboxane and leukotrienes have well-established roles in regulating both inflammation and smooth muscle contractility. Resolvins are derived from omega-3 fatty acids and have important roles in promoting the resolution of inflammation, but their activity on smooth muscle contractility is unknown. We investigated whether resolvin E1 (RvE1), resolvin D1 (RvD1) and resolvin D2 (RvD2) can modulate contractions of isolated segments of rat thoracic aorta (RTA) or human pulmonary artery (HPA) induced by the α1-adrenoceptor agonist phenylephrine or the stable thromboxane A2 mimetic U46619.
Experimental Approach: Contractile responses in RTA and HPA were measured using wire myography. Receptor expression was investigated by immunohistochemistry.
Key Results: Constriction of RTA segments by U46619, but not by phenylephrine, was significantly inhibited by pretreatment for 1 or 24 hours with 10-100 nmol/L RvE1, RvD1 or RvD2. The inhibitory effect of RvE1 was partially blocked by a chemerin receptor antagonist (CCX832). RvE1 at only 1-10 nmol/L also significantly inhibited U46619-induced constriction of HPA segments, and the chemerin receptor, GPR32 and FPR2/ALX were identified in HPA smooth muscle.
Conclusion and Implications: These data suggest that resolvins or their mimetics may prove useful novel therapeutics in diseases such as pulmonary arterial hypertension, which are characterised by increased thromboxane contractile activity.

0007-1188
1100-1108
Jannaway, Melanie
746ef6f2-a334-4d79-ae84-5f0d0d798bd9
Torrens, Christopher
15a35713-0651-4249-8227-5901e2cfcd22
Warner, Jane
8571b049-31bb-4a2a-a3c7-4184be20fe25
Sampson, Anthony
4ca76f6f-ff35-425d-a7e7-c2bd2ea2df60
Jannaway, Melanie
746ef6f2-a334-4d79-ae84-5f0d0d798bd9
Torrens, Christopher
15a35713-0651-4249-8227-5901e2cfcd22
Warner, Jane
8571b049-31bb-4a2a-a3c7-4184be20fe25
Sampson, Anthony
4ca76f6f-ff35-425d-a7e7-c2bd2ea2df60

Jannaway, Melanie, Torrens, Christopher, Warner, Jane and Sampson, Anthony (2018) Resolvin E1, resolvin D1 and resolvin D2 inhibit constriction of rat thoracic aorta and human pulmonary artery induced by the thromboxane mimetic U46619. British Journal of Pharmacology, 175 (7), 1100-1108. (doi:10.1111/bph.14151).

Record type: Article

Abstract

Background and Purpose: Omega-6 fatty acid-derived lipid mediators such as prostanoids, thromboxane and leukotrienes have well-established roles in regulating both inflammation and smooth muscle contractility. Resolvins are derived from omega-3 fatty acids and have important roles in promoting the resolution of inflammation, but their activity on smooth muscle contractility is unknown. We investigated whether resolvin E1 (RvE1), resolvin D1 (RvD1) and resolvin D2 (RvD2) can modulate contractions of isolated segments of rat thoracic aorta (RTA) or human pulmonary artery (HPA) induced by the α1-adrenoceptor agonist phenylephrine or the stable thromboxane A2 mimetic U46619.
Experimental Approach: Contractile responses in RTA and HPA were measured using wire myography. Receptor expression was investigated by immunohistochemistry.
Key Results: Constriction of RTA segments by U46619, but not by phenylephrine, was significantly inhibited by pretreatment for 1 or 24 hours with 10-100 nmol/L RvE1, RvD1 or RvD2. The inhibitory effect of RvE1 was partially blocked by a chemerin receptor antagonist (CCX832). RvE1 at only 1-10 nmol/L also significantly inhibited U46619-induced constriction of HPA segments, and the chemerin receptor, GPR32 and FPR2/ALX were identified in HPA smooth muscle.
Conclusion and Implications: These data suggest that resolvins or their mimetics may prove useful novel therapeutics in diseases such as pulmonary arterial hypertension, which are characterised by increased thromboxane contractile activity.

Text
Jannaway_et_al-2018-British_Journal_of_Pharmacology_AAM - Accepted Manuscript
Download (5MB)
Text
Jannaway_et_al-2018-British_Journal_of_Pharmacology - Version of Record
Restricted to Repository staff only
Request a copy

More information

Accepted/In Press date: 18 December 2017
e-pub ahead of print date: 20 January 2018
Published date: 9 March 2018

Identifiers

Local EPrints ID: 418904
URI: http://eprints.soton.ac.uk/id/eprint/418904
ISSN: 0007-1188
PURE UUID: d9c2e12d-fbc5-4168-a05c-0a91cf8bdbd7

Catalogue record

Date deposited: 23 Mar 2018 17:31
Last modified: 26 Nov 2021 06:45

Export record

Altmetrics

Contributors

Author: Melanie Jannaway
Author: Christopher Torrens
Author: Jane Warner
Author: Anthony Sampson

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×